Literature DB >> 24366071

Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics.

Dimitri P Mikhailidis1, Vasilios G Athyros2.   

Abstract

The new ACC/AHA guidelines on treatment of blood cholesterol focus on intensity of statin therapy rather than target levels of lipids. Early studies show substantial reductions in LDL-cholesterol level with antibodies against PCSK9. MicroRNA silencing and gene-repair techniques to treat dyslipidaemia are promising strategies under development.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24366071     DOI： 10.1038/nrcardio.2013.209

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  10 in total

1.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

2.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

3.  Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.

Authors:  Evan A Stein; Narimon Honarpour; Scott M Wasserman; Feng Xu; Rob Scott; Frederick J Raal
Journal:  Circulation       Date:  2013-09-06       Impact factor: 29.690

4.  AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.

Authors:  Nihar R Desai; Payal Kohli; Robert P Giugliano; Michelle L O'Donoghue; Ransi Somaratne; Jing Zhou; Elaine B Hoffman; Fannie Huang; William J Rogers; Scott M Wasserman; Robert Scott; Marc S Sabatine
Journal:  Circulation       Date:  2013-07-24       Impact factor: 29.690

5.  Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.

Authors:  Michael J Koren; Robert P Giugliano; Frederick J Raal; David Sullivan; Michael Bolognese; Gisle Langslet; Fernando Civeira; Ransi Somaratne; Patric Nelson; Thomas Liu; Rob Scott; Scott M Wasserman; Marc S Sabatine
Journal:  Circulation       Date:  2013-11-19       Impact factor: 29.690

6.  Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

Authors:  James M McKenney; Michael J Koren; Dean J Kereiakes; Corinne Hanotin; Anne-Catherine Ferrand; Evan A Stein
Journal:  J Am Coll Cardiol       Date:  2012-03-28       Impact factor: 24.094

7.  Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/- mice--brief report.

Authors:  Noemi Rotllan; Cristina M Ramírez; Binod Aryal; Christine C Esau; Carlos Fernández-Hernando
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-23       Impact factor: 8.311

8.  AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).

Authors:  Nihar R Desai; Robert P Giugliano; Jing Zhou; Payal Kohli; Ransi Somaratne; Elaine Hoffman; Thomas Liu; Robert Scott; Scott M Wasserman; Marc S Sabatine
Journal:  J Am Coll Cardiol       Date:  2013-10-23       Impact factor: 24.094

Review 9.  Many roads to maturity: microRNA biogenesis pathways and their regulation.

Authors:  Julia Winter; Stephanie Jung; Sarina Keller; Richard I Gregory; Sven Diederichs
Journal:  Nat Cell Biol       Date:  2009-03       Impact factor: 28.824

10.  Inducible ApoE gene repair in hypomorphic ApoE mice deficient in the low-density lipoprotein receptor promotes atheroma stabilization with a human-like lipoprotein profile.

Authors:  Delphine Eberlé; Fu Sang Luk; Roy Y Kim; Victor R Olivas; Nikit Kumar; Jessica M Posada; Kang Li; Nathalie Gaudreault; Joseph H Rapp; Robert L Raffai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-06-20       Impact factor: 8.311
  10 in total
  2 in total

1.  Attainment of multifactorial treatment targets among the elderly in a lipid clinic.

Authors:  Fotios Barkas; Evangelos Liberopoulos; Eleftherios Klouras; Angelos Liontos; Moses Elisaf
Journal:  J Geriatr Cardiol       Date:  2015-05       Impact factor: 3.327

2.  SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.

Authors:  Jaroslav A Hubáček; Dana Dlouhá; Vera Adámková; Lukáš Zlatohlavek; Ondřej Viklický; Petra Hrubá; Richard Češka; Michal Vrablík
Journal:  Med Sci Monit       Date:  2015-05-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.